Delineation of the apoptotic cascade induced by the proteasome inhibitor PS-341 in human multiple myeloma cells using microarray profiling and functional analysis: Clinical implications.

被引:0
|
作者
Mitsiades, N
Mitsiades, CS
Poulaki, V
Chauhan, D
Fanourakis, G
Gu, XS
Bailey, C
Joseph, M
Libermann, TA
Richardson, PG
Munshi, NC
Hideshima, T
Anderson, KC
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA
[3] Harvard Inst Med, Beth Israel Deaconess Med Ctr, Genom Ctr, Boston, MA USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
3221
引用
收藏
页码:815A / 815A
页数:1
相关论文
共 14 条
  • [1] The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
    Hideshima, T
    Richardson, P
    Chauhan, D
    Palombella, VJ
    Elliott, PJ
    Adams, J
    Anderson, KC
    CANCER RESEARCH, 2001, 61 (07) : 3071 - 3076
  • [2] Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model.
    LeBlanc, R
    Catley, L
    Hideshima, T
    Pien, CS
    Elliott, PJ
    Anderson, KC
    BLOOD, 2001, 98 (11) : 774A - 774A
  • [3] The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents
    Ma, MH
    Yang, HH
    Parker, K
    Manyak, S
    Friedman, JM
    Altamirano, C
    Wu, ZQ
    Borad, MJ
    Frantzen, M
    Roussos, E
    Neeser, J
    Mikail, A
    Adams, J
    Sjak-Shie, N
    Vescio, RA
    Berenson, JR
    CLINICAL CANCER RESEARCH, 2003, 9 (03) : 1136 - 1144
  • [4] The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    Mitsiades, N
    Mitsiades, CS
    Richardson, PG
    Poulaki, V
    Tai, YT
    Chauhan, D
    Fanourakis, G
    Gu, XS
    Bailey, C
    Joseph, M
    Libermann, TA
    Schlossman, R
    Munshi, NC
    Hideshima, T
    Anderson, KC
    BLOOD, 2003, 101 (06) : 2377 - 2380
  • [5] Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
    Chauhan, D
    Li, GL
    Podar, K
    Hideshima, T
    Mitsiades, C
    Schlossman, R
    Munshi, N
    Richardson, P
    Cotter, FE
    Anderson, KC
    BLOOD, 2004, 104 (08) : 2458 - 2466
  • [6] The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma (MM) cells.
    Hideshima, T
    Richardson, PG
    Chauhan, D
    Palombella, VJ
    Elliott, PJ
    Adams, J
    Anderson, KC
    BLOOD, 2000, 96 (11) : 461A - 461A
  • [7] The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications.
    Mitsiades, N
    Mitsiades, CS
    Richardson, PG
    Poulaki, V
    Fanourakis, G
    Tai, YT
    Chauhan, D
    Schlossman, R
    Munshi, NC
    Hideshima, T
    Anderson, KC
    BLOOD, 2002, 100 (11) : 105A - 106A
  • [8] Gene expression analysis of tumor cells sensitive and resistant to PS-341 (Bortezomib) treatment: Clinical implications.
    Shringarpure, R
    Chauhan, D
    Burger, R
    Catley, L
    Tai, YT
    Podar, K
    Hideshima, T
    Mitsiades, N
    Mitsiades, C
    Anderson, KC
    BLOOD, 2003, 102 (11) : 180A - 181A
  • [9] Bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic apoptosis in multiple myeloma (MM) cells
    Chauhan, D
    Li, GL
    Hideshima, T
    Podar, K
    Catley, L
    Munshi, N
    Sporn, MB
    Anderson, KC
    BLOOD, 2003, 102 (11) : 935A - 935A
  • [10] Apoptotic signaling induced by immunomodulatory thalidomide analogs (IMiDs) in human multiple myeloma cells: Therapeutic implications.
    Mitsiades, N
    Mitsiades, CS
    Poulaki, V
    Akiyama, M
    Tai, YT
    Lin, BK
    Hayashi, T
    Catley, L
    Hideshima, T
    Chauhan, D
    Treon, SP
    Anderson, KC
    BLOOD, 2001, 98 (11) : 775A - 775A